Structural and Enzyme Kinetic Basis Underpinning the Activity of 4-Anilinoquinazoline-Based Fourth-Generation EGFR Inhibitors

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of EGFR mutant non-small cell lung cancer (NSCLC). The EGFR gatekeeper mutation T790M confers resistance to first-generation EGFR inhibitors that act through ATP competition by increasing the affinity of the kinase for ATP. Third-generation inhibitors partially overcome this limitation by forming a covalent bond with Cys797, thereby enhancing their ability to compete with ATP; however, the C797S mutation abolishes this covalent interaction and leads to renewed drug resistance. To overcome C797S-mediated resistance, a range of so-called fourth-generation inhibitors have been developed, some of which retain the classical 4-anilinoquinazoline scaffold. In this study, we compared the potencies of two such candidate compounds, BDTX-1535 and WSD0922, together with first- and second-generation inhibitors that also share the 4-anilinoquinazoline scaffold, in clinically relevant cell models harboring EGFR C797S with or without T790M mutation. By combining the experimentally determined structure of EGFR/BDTX-1535 complex, molecular docking models of WSD0922, and analysis of the effects of the C797S mutation on EGFR kinase kinetics, we sought to explore structural and enzymatic factors associated with differences in inhibitor potency. These findings provide comparative insight into the behavior of 4-anilinoquinazoline-based EGFR inhibitors and may help guide subsequent inhibitor optimization.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-21
DOI
https://doi.org/10.1021/acsomega.6c06071
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Structural and Enzyme Kinetic Basis Underpinning the Activity of 4-Anilinoquinazoline-Based Fourth-Generation EGFR Inhibitors

Cai‐Hong Yun, Xianming Deng, Lulu Kong, Jia Hao et al.
ACS Omega
Lung Cancer Treatments and Mutations
article

Structural and Enzyme Kinetic Basis Underpinning the Activity of 4-Anilinoquinazoline-Based Fourth-Generation EGFR Inhibitors

Cai‐Hong Yun, Xianming Deng, Lulu Kong, Jia Hao, Rui Han, Xiao-E Yan, Wei Huang, Xi Luo
article en

Abstract

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of EGFR mutant non-small cell lung cancer (NSCLC). The EGFR gatekeeper mutation T790M confers resistance to first-generation EGFR inhibitors that act through ATP competition by increasing the affinity of the kinase for ATP. Third-generation inhibitors partially overcome this limitation by forming a covalent bond with Cys797, thereby enhancing their ability to compete with ATP; however, the C797S mutation abolishes this covalent interaction and leads to renewed drug resistance. To overcome C797S-mediated resistance, a range of so-called fourth-generation inhibitors have been developed, some of which retain the classical 4-anilinoquinazoline scaffold. In this study, we compared the potencies of two such candidate compounds, BDTX-1535 and WSD0922, together with first- and second-generation inhibitors that also share the 4-anilinoquinazoline scaffold, in clinically relevant cell models harboring EGFR C797S with or without T790M mutation. By combining the experimentally determined structure of EGFR/BDTX-1535 complex, molecular docking models of WSD0922, and analysis of the effects of the C797S mutation on EGFR kinase kinetics, we sought to explore structural and enzymatic factors associated with differences in inhibitor potency. These findings provide comparative insight into the behavior of 4-anilinoquinazoline-based EGFR inhibitors and may help guide subsequent inhibitor optimization.

ACS Omega
Xiamen University (CN), Peking University (CN), Chengdu University of Traditional Chinese Medicine (CN)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon